Furthermore, the more aggressive expression of FOXD3-AS1 in SCLC over that in NSCLC (LUAD and LUSC) at early or all stages may be due to the fact that SCLC has a different pathological mechanism from NSCLC, such as a strong predilection for early metastasis [30]. Here, FOXD3 is linked to small cell lung carcinoma.